RISA Labs, a healthtech startup focused on improving cancer care workflows, has raised $3.5 million in a seed funding round led by Binny Bansal (Flipkart co-founder). The round also saw participation from Oncology Ventures, General Catalyst, z21 Ventures, ODD BIRD VC, and angel investor Ashish Gupta.
The funds raised will be used to deploy its AI-based automation platform across 100 cancer centers in the US over the next two years.
“We’ve had Windows, we’ve had Linux, we’ve had Mac, each OS helped humans extract more from machines. But now, we’re drowning in software. There’s too much of it, and a shortage of skilled labor to operate it. Software that was supposed to get work done has become work itself. BOSS is an AI OS designed for the post-ChatGPT era: where work is no longer about learning tools, but simply expressing intent,” said Kshitij Jaggi, co-founder and CEO of RISA Labs.
“BOSS is low-entropy system design to bring flow state in system-2 thinking for LLMs; it aims to maximise AI agents’ usefulness for critical problems like oncology operations. Its orchestration layer then turns that intelligence into precise, real-time execution with integrations with systems of record like Flatiron Health’s EMR,” said Kumar Shivang, co-founder & CTO of RISA.
“As AI agents unbundle the $4.6 trillion services industry, RISA’s BOSS leads the way—proven in oncology and built to scale,” said Binny Bansal, co-founder of Flipkart and lead investor.
“Prior authorizations remain one of the least automated parts of our healthcare system. In oncology, the stakes are higher. 70% of cancer patients experience delays in care because of prior authorization requirements. In 33% of those cases, the delay is one month—a time window that can increase the risk of death by 13% in certain cancer types. The current system isn’t just inefficient – it’s dangerous,” said Ben Freeberg, Managing Partner at Oncology Ventures.
Founded in 2024 by Kshitij Jaggi (CEO) and Kumar Shivang (CTO), Risa offers a workflow orchestration platform called BOSS (Business Operating System as a Service). RISA’s platform leverages agentic AI, digital twins, and LLMs to deconstruct complex workflows into micro-tasks and execute them with unprecedented efficiency.
Risa Labs claims to reduce prior authorization times from 30 minutes to under five. In just a few months, it processed over $1 million in medications, freed up 80% of staff time, and cut administrative costs by 66%.
Risa plans to extend its platform across multiple nodes of the oncology ecosystem, enabling greater coordination and intelligence among providers, life sciences organisations, and other stakeholders as the company aims to build a unified layer for AI-driven orchestration throughout the drug lifecycle.
